Taming microglia: the promise of engineered microglia in treating neurological diseases

Echo Yongqi Luo,Rio Ryohichi Sugimura
DOI: https://doi.org/10.1186/s12974-024-03015-9
IF: 9.3
2024-01-13
Journal of Neuroinflammation
Abstract:Microglia, the CNS-resident immune cells, are implicated in many neurological diseases. Nearly one in six of the world's population suffers from neurological disorders, encompassing neurodegenerative and neuroautoimmune diseases, most with dysregulated neuroinflammation involved. Activated microglia become phagocytotic and secret various immune molecules, which are mediators of the brain immune microenvironment. Given their ability to penetrate through the blood–brain barrier in the neuroinflammatory context and their close interaction with neurons and other glial cells, microglia are potential therapeutic delivery vehicles and modulators of neuronal activity. Re-engineering microglia to treat neurological diseases is, thus, increasingly gaining attention. By altering gene expression, re-programmed microglia can be utilized to deliver therapeutics to targeted sites and control neuroinflammation in various neuroinflammatory diseases. This review addresses the current development in microglial engineering, including genetic targeting and therapeutic modulation. Furthermore, we discuss limitations to the genetic engineering techniques and models used to test the functionality of re-engineered microglia, including cell culture and animal models. Finally, we will discuss future directions for the application of engineered microglia in treating neurological diseases.
immunology,neurosciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to treat neurological diseases such as neurodegenerative diseases and brain tumors by re - engineering microglia. Specifically: 1. **Neurodegenerative diseases**: Microglia play a crucial role in neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD). The paper explores ways to re - design microglia through gene editing or drug delivery to reduce the accumulation of pathological proteins (such as Aβ and α - synuclein), thereby reducing the inflammatory response and neuronal damage. For example, by inhibiting the activity of the BACE - 1 enzyme, the production of Aβ can be reduced, thereby alleviating the symptoms of AD. 2. **Brain tumors (such as glioblastoma)**: Microglia usually exhibit a pro - tumor phenotype in the brain tumor microenvironment. The paper discusses how to reprogram microglia from a pro - tumor phenotype to an anti - tumor phenotype through genetic engineering means (such as using the rAAV2 - IL - 15 viral vector) or nanotechnology (such as drug - loaded nanogels) by means of genetic engineering, thereby inhibiting tumor growth and promoting the anti - tumor activity of immune cells. 3. **Neuroinflammation**: Microglia play an important role in various neuroinflammatory diseases. The paper proposes to regulate the inflammatory response of microglia through gene editing or drug delivery to control neuroinflammation and thus treat related diseases. In conclusion, this paper aims to develop new treatment methods by re - designing microglia and using their unique biological characteristics to deal with currently incurable neurological diseases.